Bellicum Pharmaceuticals (BLCM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Bellicum Pharmaceuticals (BLCM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Bellicum Pharmaceutical (NASDAQ: BLCM) stock has remarkably little going for it. A development stage pharmaceutical company the market capitalisation is around the $3 million level. The short position ...

Shares of Bellicum Pharmaceuticals BLCM lost 50.1% on Mar 15 after management announced that it has decided to discontinue the ongoing phase I/II studies evaluating its GoCAR-T cell product candidates ...

Shares of Bellicum Pharmaceuticals (BLCM) have been struggling lately and have lost 12% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean ...

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 ...

Bellicum Pharmaceuticals Inc has a consensus price target of $5, established from looking at the 1 latest analyst ratings. The last 1 analyst ratings were released from Ladenburg Thalmann on February ...